JMKX003948
/ Jemincare
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 18, 2025
Study of JMKX003948 Ophthalmic Suspension in Healthy Participants
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Jemincare
New P1 trial • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders
July 09, 2024
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Jemincare | Not yet recruiting ➔ Recruiting
Enrollment open • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
March 21, 2024
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
(clinicaltrials.gov)
- P1 | N=80 | Not yet recruiting | Sponsor: Jemincare
New P1 trial • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
December 26, 2023
Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs
(BioSpace)
- "On November 28, NMPA has approved a clinical trial for JMKX003948 to treat renal cell carcinoma....On December 12, FDA has approved a clinical trial for JMKX000197 to treat BCG-unresponsive non-muscle-invasive bladder cancer, and earlier on October 19, NMPA has approved the clinical trial."
IND • New trial • Bladder Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
1 to 4
Of
4
Go to page
1